Anyone who has seriously followed the research on COVID will tell you that the risk of myocarditis (among numerous other conditions) from COVID is far greater than that of Novavax.
The 3CL protease, a critical part of the viral machinery that allows SARS-CoV-2 to replicate, binds with hundreds of proteins in the liver and gut alone.
And for anyone that is concerned about spike protein, you should be concerned about the thing that is able to generate on the order of trillions of them in your own body.
Only the virus can do that. Not Novavax. Not even mRNA.
There are forces out there that want us bitterly divided. Isolated. Attacking our peers with differing political opinions.
Here's the truth: COVID informed people don't want lockdowns. We don't want to force you to get vaccines.
What do COVID informed people want?
Speaking for myself, I want biosecurity by default. I want far-UVC in public buildings. I want ventilation. I want access to treatments of my choosing.
I don't want people to sleepwalk into decreased quality of life. That's the status quo.
That encompasses why I even bother spending time on X instead of lurking away silently on the sidelines as another invisible, everyday person.
I can't afford not to try making things better. My family can't afford the status quo. Nobody can. Not even billionaires.
So when you see the likes of Vinay Prasad intervening in FDA scientific decisions, recognize that this too will pass.
Eventually, technology will evolve and so too will our demand for non-invasive mitigations.
And until those mitigations are commonplace, I'm not going anywhere.
Correction: I had meant to say liver and kidneys on this post, although viral persistence has been demonstrated in the gut in separate studies.
This will be the first time Novavax is available outside of Emergency Use Authorization.
Getting access to it this year may require a bit of extra effort, since the new license stipulates that most must have an underlying condition to access the vaccine.
I can appreciate skepticism of long COVID as a concept. After all, it may instinctually seem like an epistemological overreach to assign a singular cause to such a heterogeneous disease presentation.
On the other hand, consider the localization of ACE2 throughout your body. Consider the reach of your blood vessels. Couple that with imaging studies that demonstrate spike persistence in areas such as the brain and skull. Consider also that viral persistence has been identified in the gut with replication competent virus.
In the last few years, I've interacted with tons of people on this platform, both vaccinated and unvaccinated, who have lost a significant amount of mobility after having had COVID infections. Healthy and unhealthy, comorbidities or not. People in their 40s are also dying of rare cancers. Athletes and soldiers are having a decrease in functional performance after a single COVID infection, let alone reinfections.
The deeper you look into viral persistence (look at the work Polybio and Erturk Lab are doing on imaging, for example), the more you'll find yourself willing to consider that COVID might play a role in it.
The key is in recognizing that the microvascular changes COVID causes are difficult to detect with off-the-shelf diagnostics. Once research develops more readily commoditized diagnostics, perhaps the condition will gain wider recognition. In the meantime we have a large segment of young, middle-aged, and previously healthy athletes succumbing to unusually debilitating chronic illness after COVID infections. That illness is real despite misgivings some may have. And so too is the underlying damage COVID causes, even if it's not straightforward to detect in all instances. Whatever you want to call the disease, those patients deserve medical treatment despite limitations in the diagnostic tools conventionally available.
For the month of March, NB.1.8.1 went from having single digit prevalence in Hong Kong to 80%.
It achieved 100% dominance in HK by late April.
NB.1.8.1 has also been spreading to Thailand, South Korea, Taiwan, and Japan (which saw a 30% prevalence of the variant at the beginning of April to 70% prevalence by the end of the month).